gouya insights logo 2

8. November 2021: Advancing Research : Gouya Insights holds Free Expert Consultation for clinical trials

PRESS RELEASE

Advancing Research: Gouya Insights holds Free Expert Consultation for clinical trials

Vienna, 08.11.2021 – Clinical trials are a central component of medical research. Without such trials, there would be no approved drugs and medical development would come to a standstill.

PD Dr. Ghazaleh Gouya Lechner wants to further promote the development of clinical trials and is now offering a free and virtual expert consultation hour. With this weekly expert hour, Gouya Insights aims at offering doctors, scientists, biotech and MedTech companies as well as all those involved in the drugs clinical development, a platform with professional expertise that stimulate exchange.

The aim is to strengthen Austria as a research location in the long term. “In our expert consultation, initial information on common understanding, regulatory requirements, scope, duration, design and budget of a clinical trial is to be discussed,” explains PD Dr. Ghazaleh Gouya Lechner about her latest project. “After discussing, the participants have a clear idea of what is needed to enter the clinical phase, the approximate effort and scale of the trial, as well as a cost estimate.”

The specialist in internal medicine, cardiology and clinical pharmacology has many years of clinical and scientific experience as well as special expertise in clinical research. In 2016, she founded her own company, making it the Austrian industry leader in the field of clinical development. Her approach is always practice-oriented and science-led.

The expert hours will take place every Monday morning, via teleconference. For preparation purposes, please contact office@gouya-insights.com.

Schedule Your Expert Hour

Get INSIGHTS into the strategies you need for a successful clinical trial!

Share This Post

More To Explore

EU CTR: Transparency

Wien, 15.04.2024 – Text: Catarina Carrão In the end of January 2022, the EU CTR (EU/536/2014) came into effect within the European Union (EU), replacing